Greenwich LifeSciences Inc. has announced the extension of the lock-up period for shares owned by the company's directors, officers, and certain pre-IPO investors to September 30, 2026. This move is intended to support the ongoing Phase III clinical trial, FLAMINGO-01, which is evaluating the Fast Track designated immunotherapy GLSI-100 for the prevention of breast cancer recurrences. Preliminary open label data from FLAMINGO-01, including recurrence rate, immune response, and safety, has been collected and analyzed in a manner that maintains the study blind. However, this data is not yet complete or fully reviewed and remains preliminary. Comparison of these early results to previous Phase IIb data may be possible, but the final outcomes of the ongoing trial have not yet been determined or presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617702-en) on December 29, 2025, and is solely responsible for the information contained therein.